Budget Impact of Lasmiditan for the Acute Treatment of Migraine in the United States

被引：0
|
作者：
Milev, S. [1 ]
Pohl, G. M. [2 ]
Sun, A. [1 ]
Mason, O. [2 ]
Njuguna, N. [2 ]
Loo, L. [2 ]
机构：
[1] Evidera Inc, San Francisco, CA USA
[2] Eli Lilly, Indianapolis, IN USA
来源：
HEADACHE | 2020年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：64 / 64
页数：1
相关论文
共 50 条
  • [41] Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan Compared to Placebo for Acute Treatment of Migraine
    Wietecha, L.
    Kuca, B.
    Asafu-Adjei, J.
    Aurora, S.
    HEADACHE, 2018, 58 : 73 - 73
  • [42] TALTZ® (IXEKIZUMAB) FOR TREATMENT OF PSORIATIC ARTHRITIS IN THE UNITED STATES: A BUDGET IMPACT ANALYSIS
    Murage, M.
    Panchmatia, H.
    Patel, S.
    Birt, J.
    Gellet, A. M.
    Sprabery, A. T.
    Malatestinic, B.
    Atiya, B.
    Kern, S.
    Kadambi, A.
    VALUE IN HEALTH, 2020, 23 : S220 - S221
  • [43] BUDGET IMPACT ANALYSIS OF ESKETAMINE IN TREATMENT-RESISTANT DEPRESSION IN THE UNITED STATES
    Le, H. H.
    Zhang, Q.
    Sheehan, J. J.
    VALUE IN HEALTH, 2019, 22 : S229 - S230
  • [44] BUDGET IMPACT ANALYSIS OF NEFECON FOR THE TREATMENT OF PRIMARY IGA NEPHROPATHY IN THE UNITED STATES
    Hwang, S.
    Ramjee, L.
    Patel, M.
    Ngai, C.
    Tremblay, G.
    VALUE IN HEALTH, 2022, 25 (07) : S400 - S400
  • [45] Budget impact of Ontruzant for the treatment of breast cancer and gastric cancer in the United States
    Huang, Min
    Singhal, Puneet
    Shinde, Reshma
    Wilkes, Sarah K.
    Nagda, Nirav
    Yi, Yunni
    Lucherini, Stefano
    CANCER RESEARCH, 2021, 81 (04)
  • [46] Phase 3 studies (SAMURAI, SPARTAN) of lasmiditan compared to placebo for acute treatment of migraine
    Wietecha, Linda A.
    Kuca, Bernice
    Asafu-Adjei, Josephine
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [47] Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan Compared to Placebo for Acute Treatment of Migraine
    Wietecha, Linda A.
    Kuca, Bernice
    Asafu-Adjei, Josephine
    Aurora, Sheena K.
    NEUROLOGY, 2018, 90
  • [48] Selection drivers for recently prescribed lasmiditan, ubrogepant, or rimegepant for the acute treatment of migraine: Results from an annual cross-sectional patient chart audit in the United States
    Schobel, V. R.
    HEADACHE, 2021, 61 : 146 - 147
  • [49] Trajectory of migraine-related disability over 12 months with lasmiditan for acute treatment of migraine in the GLADIATOR Study
    Loo, Li Shen
    Buse, Dawn
    Lombard, Louise
    Ruff, Dustin
    Krege, John
    Buchanan, Andy
    Lipton, Richard
    NEUROLOGY, 2020, 94 (15)
  • [50] Phase-3 study (SPARTAN) of Lasmiditan compared to placebo for acute treatment of migraine
    Wietecha, L. A.
    Kuca, B.
    Case, M. G.
    Selzler, K. J.
    Aurora, S. K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 79 - 79
12345